FIELD: immunology.
SUBSTANCE: present invention relates to immunology, in particular to a method for the treatment of cancer characterized by Trop-2 expression. The method includes the injection to a subject of an antibody-drug conjugate SN-38 (irinotecan) in a combination with Rad51 inhibitor. The specified conjugate is known as IMMU-132 (satsituzumab govitecan). B02 or RI-1 can be used as Rad51 inhibitor. The specified combination of the conjugate and Rad51 inhibitor can reduce the size of solid tumors, reduce or eliminate metastases and is effective for the treatment of cancer diseases resistant to standard treatment methods, such as radiation therapy, chemotherapy or immunotherapy.
EFFECT: present invention allows improving the efficiency of methods for the therapy of a cancer expressing Trop-2.
26 cl, 36 dwg, 5 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| EFFICACY OF CONJUGATES OF ANTI-TROP-2 ANTIBODY WITH DRUG SN-38 FOR THERAPY OF RECURRENT/REFRACTORY TO INHIBITORS OF TUMOR CONTROL POINT | 2017 |
|
RU2725292C2 |
| ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2743077C2 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES | 2014 |
|
RU2801307C1 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| COMPOSITION FOR TREATING CANCER, COMBINING ANTI-CD26 ANTIBODY AND OTHER ANTI-CANCER AGENT | 2016 |
|
RU2742953C2 |
